Skip to content
Research Article Open access CC BY 4.0

Visfatin Level in Diabetic and Non-diabetic Chronic Kidney Diseases

Samer S. Zekry, Maher A. Al Amir, Mohamed A. Mashahit, Hoiyda A. Abd El-Rasol, Ehab A. Hassan

Asian Journal of Medicine and Health · pp. 1–11 · Published 12 Sep 2017

10.9734/AJMAH/2017/36085

Abstract

Introduction: Chronic kidney disease (CKD) has become a global public health threat. The irreversible nature of the disease, its association with significant morbidity and mortality as well as the cost of renal replacement therapy leads to a large burden for health care providers, particularly in developing countries like Egypt. Objective: To find a non-invasive method to evaluate association of serum visfatin with chronic kidney disease secondary to diabetic nephropathy and compare to patients with chronic kidney disease secondary to other causes. Methods: Ninety individuals including 30 healthy controls and 60 patients of CKD were included in this study. Patients with CKD were further grouped based on etiology of CKD into 30 diabetic patients and 30 non-diabetic patients. Patients with type 1 diabetes mellitus, urinary tract           infection, urolithiasis, liver cirrhosis, stroke, ischemic heart disease, and rheumatoid arthritis were excluded. Measurement of serum visfatin was done through ELISA Kit (Elabscience pharmaceuticals). Results: Visfatin concentration was significantly high in patients with CKD compared to controls (p < 0 .001). No significant difference in Visfatin concentrations between patients of CKD with and without diabetes was detected (p > 0.05). Visfatin concentration was significantly high in patients with CKD stage 2 compared to CKD stage 1 (p < 0 .001). Conclusion: The present study confirms the association of visfatin with CKD, however further studies at molecular level to check its expression within renal tissue may clarify its definitive role in CKD.  

Visfatin chronic kidney disease diabetes mellitus

References (10)

  1. 1 Prevalence of Chronic Kidney Disease in the United States [DOI]
  2. 2 Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus [DOI]
  3. 3 Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin [DOI]
  4. 4 Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. [DOI]
  5. 5 Circulating Levels of Visfatin/Pre–B-Cell Colony–Enhancing Factor 1 in Relation to Genotype, GFR, Body Composition, and Survival in Patients With CKD [DOI]
  6. 6 Uncovering Suitable Reference Proteins for Expression Studies in Human Adipose Tissue with Relevance to Obesity [DOI]
  7. 7 Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
  8. 8 Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
  9. 9 CORRELATIONS OF VISFATIN WITH THE LIPIDIC METABOLISM IN DIABETIC AND OBESE PATIENTS
  10. 10 The Epidemiology of Diabetic Kidney Disease [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.